JP2016537347A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016537347A5 JP2016537347A5 JP2016529960A JP2016529960A JP2016537347A5 JP 2016537347 A5 JP2016537347 A5 JP 2016537347A5 JP 2016529960 A JP2016529960 A JP 2016529960A JP 2016529960 A JP2016529960 A JP 2016529960A JP 2016537347 A5 JP2016537347 A5 JP 2016537347A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- weight
- compound
- combination
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 173
- 150000001875 compounds Chemical class 0.000 claims description 106
- 239000000203 mixture Substances 0.000 claims description 65
- 150000003840 hydrochlorides Chemical class 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 51
- 239000000945 filler Substances 0.000 claims description 43
- 239000011230 binding agent Substances 0.000 claims description 40
- 239000007884 disintegrant Substances 0.000 claims description 40
- 239000000314 lubricant Substances 0.000 claims description 39
- 239000008187 granular material Substances 0.000 claims description 32
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 24
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 20
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 20
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 20
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 20
- 229910052751 metal Inorganic materials 0.000 claims description 18
- 239000002184 metal Substances 0.000 claims description 18
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 16
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 14
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 14
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 14
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 12
- 229960001375 lactose Drugs 0.000 claims description 12
- 239000008101 lactose Substances 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- 229920002472 Starch Polymers 0.000 claims description 10
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 10
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 10
- 239000008107 starch Substances 0.000 claims description 10
- 235000019698 starch Nutrition 0.000 claims description 10
- 229940032147 starch Drugs 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 229920000858 Cyclodextrin Polymers 0.000 claims description 8
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 8
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 8
- 239000004359 castor oil Substances 0.000 claims description 8
- 235000019438 castor oil Nutrition 0.000 claims description 8
- 229960005168 croscarmellose Drugs 0.000 claims description 8
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 8
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims description 8
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 8
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 8
- -1 polyplastidone Polymers 0.000 claims description 8
- 239000003002 pH adjusting agent Substances 0.000 claims description 7
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 239000003443 antiviral agent Substances 0.000 claims description 6
- 239000008139 complexing agent Substances 0.000 claims description 6
- 229960000913 crospovidone Drugs 0.000 claims description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 6
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 6
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 6
- 235000000346 sugar Nutrition 0.000 claims description 6
- 241000712461 unidentified influenza virus Species 0.000 claims description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 5
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 4
- 239000001116 FEMA 4028 Substances 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
- 229940123424 Neuraminidase inhibitor Drugs 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 229940123066 Polymerase inhibitor Drugs 0.000 claims description 4
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 4
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 4
- 229960004853 betadex Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 229960001021 lactose monohydrate Drugs 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 235000021317 phosphate Nutrition 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 239000008363 phosphate buffer Substances 0.000 claims description 4
- 229920000136 polysorbate Polymers 0.000 claims description 4
- 229950008882 polysorbate Drugs 0.000 claims description 4
- 239000002911 sialidase inhibitor Substances 0.000 claims description 4
- 239000001488 sodium phosphate Substances 0.000 claims description 4
- 229940071117 starch glycolate Drugs 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 239000000080 wetting agent Substances 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 3
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- 241000712431 Influenza A virus Species 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 2
- 235000019800 disodium phosphate Nutrition 0.000 claims description 2
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 claims description 2
- 229950008454 favipiravir Drugs 0.000 claims description 2
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 2
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 2
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims description 2
- 229960003752 oseltamivir Drugs 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Substances [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 2
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 2
- 239000008109 sodium starch glycolate Substances 0.000 claims description 2
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims description 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 229960001028 zanamivir Drugs 0.000 claims description 2
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims description 2
- MHQJUHSHQGQVTM-VHEBQXMUSA-N (e)-4-octadecoxy-4-oxobut-2-enoic acid Chemical class CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C(O)=O MHQJUHSHQGQVTM-VHEBQXMUSA-N 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 230000029812 viral genome replication Effects 0.000 claims 1
- MHQJUHSHQGQVTM-HNENSFHCSA-N Octadecyl fumarate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)\C=C/C(O)=O MHQJUHSHQGQVTM-HNENSFHCSA-N 0.000 description 2
- 229940071138 stearyl fumarate Drugs 0.000 description 2
- JGPXDNKSIXAZEQ-UHFFFAOYSA-N OC(C(C1CCC2CC1)C2Nc1nc(-c2c[nH]c(nc3)c2cc3F)ncc1F)=O Chemical compound OC(C(C1CCC2CC1)C2Nc1nc(-c2c[nH]c(nc3)c2cc3F)ncc1F)=O JGPXDNKSIXAZEQ-UHFFFAOYSA-N 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021152005A JP2021191796A (ja) | 2013-11-13 | 2021-09-17 | アザインドール化合物の製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361903840P | 2013-11-13 | 2013-11-13 | |
| US61/903,840 | 2013-11-13 | ||
| PCT/US2014/065144 WO2015073491A1 (en) | 2013-11-13 | 2014-11-12 | Formulations of azaindole compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021152005A Division JP2021191796A (ja) | 2013-11-13 | 2021-09-17 | アザインドール化合物の製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016537347A JP2016537347A (ja) | 2016-12-01 |
| JP2016537347A5 true JP2016537347A5 (enExample) | 2017-12-21 |
Family
ID=52001095
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016529960A Pending JP2016537347A (ja) | 2013-11-13 | 2014-11-12 | アザインドール化合物の製剤 |
| JP2021152005A Pending JP2021191796A (ja) | 2013-11-13 | 2021-09-17 | アザインドール化合物の製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021152005A Pending JP2021191796A (ja) | 2013-11-13 | 2021-09-17 | アザインドール化合物の製剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20160250213A1 (enExample) |
| EP (1) | EP3068434A1 (enExample) |
| JP (2) | JP2016537347A (enExample) |
| KR (1) | KR20160084465A (enExample) |
| CN (1) | CN105848683A (enExample) |
| AU (1) | AU2014348762A1 (enExample) |
| CA (1) | CA2930105A1 (enExample) |
| CL (1) | CL2016001111A1 (enExample) |
| IL (2) | IL245587A0 (enExample) |
| MX (1) | MX2016006197A (enExample) |
| RU (1) | RU2685730C1 (enExample) |
| SG (1) | SG10201804024VA (enExample) |
| WO (1) | WO2015073491A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20207129B (en) | 2009-06-17 | 2020-07-10 | Vertex Pharma | Inhibitors of influenza viruses replication |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| HRP20191525T1 (hr) | 2013-11-13 | 2019-11-29 | Vertex Pharma | Inhibitori replikacije virusa influence |
| EP3421468B1 (en) | 2013-11-13 | 2020-11-04 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
| JP6704416B2 (ja) | 2015-05-13 | 2020-06-03 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | インフルエンザウイルスの複製の阻害剤を調製する方法 |
| WO2016183120A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| EP3362451B1 (en) | 2015-12-09 | 2023-04-12 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication, application methods and uses thereof |
| WO2018033082A1 (en) | 2016-08-16 | 2018-02-22 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication, application methods and uses thereof |
| CN109641868B (zh) | 2016-08-30 | 2021-12-03 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其使用方法和用途 |
| JP7034162B2 (ja) * | 2016-12-15 | 2022-03-11 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | インフルエンザウイルス複製の阻害剤及びその使用 |
| WO2018127096A1 (en) | 2017-01-05 | 2018-07-12 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
| US10815232B2 (en) | 2017-01-24 | 2020-10-27 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystalline forms of viral-protein inhibitor drug VX-787, processes for preparation thereof and use thereof |
| CN110446711B (zh) | 2017-03-02 | 2022-02-15 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其用途 |
| EP3609502A1 (en) * | 2017-04-12 | 2020-02-19 | Vertex Pharmaceuticals Incorporated | Combination therapies for treating influenza virus infection |
| WO2019043614A1 (en) * | 2017-08-31 | 2019-03-07 | Novartis Ag | PROCESS FOR THE PREPARATION OF GRANULES |
| US20210147413A1 (en) * | 2018-04-06 | 2021-05-20 | Janssen Pharmaceuticals, Inc. | Isothermal reactive crystallisation process for the preparation of a crystalline form of pimodivir hydrochloride hemihydrate |
| WO2020058745A1 (en) * | 2018-09-18 | 2020-03-26 | Shionogi & Co., Ltd. | Treating influenza using substituted polycyclic pyridone derivatives and prodrugs thereof |
| US12156876B2 (en) * | 2018-11-13 | 2024-12-03 | Cocrystal Pharma, Inc. | Formulations of influenza therapeutics |
| KR20200106607A (ko) * | 2019-03-05 | 2020-09-15 | 주식회사 코아팜바이오 | 오셀타미비르 함유 의약 조성물 |
| WO2020256820A1 (en) * | 2019-06-20 | 2020-12-24 | Janssen Pharmaceuticals, Inc. | Formulations of azaindole compounds |
| CN112578034B (zh) * | 2020-11-04 | 2022-02-11 | 广东众生睿创生物科技有限公司 | 一种手性胺小分子及其盐的质量控制方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681815A (en) * | 1993-06-28 | 1997-10-28 | Sophie Chen | Antiviral and antitumor agents |
| EP2486942B1 (en) * | 2004-11-24 | 2018-10-10 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
| WO2010143207A1 (en) * | 2009-06-11 | 2010-12-16 | Rubicon Research Private Limited | Taste-masked oral formulations of influenza antivirals |
| GEP20207129B (en) * | 2009-06-17 | 2020-07-10 | Vertex Pharma | Inhibitors of influenza viruses replication |
-
2014
- 2014-11-12 MX MX2016006197A patent/MX2016006197A/es unknown
- 2014-11-12 WO PCT/US2014/065144 patent/WO2015073491A1/en not_active Ceased
- 2014-11-12 JP JP2016529960A patent/JP2016537347A/ja active Pending
- 2014-11-12 SG SG10201804024VA patent/SG10201804024VA/en unknown
- 2014-11-12 EP EP14805749.0A patent/EP3068434A1/en not_active Withdrawn
- 2014-11-12 CA CA2930105A patent/CA2930105A1/en not_active Abandoned
- 2014-11-12 CN CN201480071163.7A patent/CN105848683A/zh active Pending
- 2014-11-12 AU AU2014348762A patent/AU2014348762A1/en not_active Abandoned
- 2014-11-12 KR KR1020167015721A patent/KR20160084465A/ko not_active Ceased
- 2014-11-12 RU RU2016122609A patent/RU2685730C1/ru active
-
2016
- 2016-05-10 CL CL2016001111A patent/CL2016001111A1/es unknown
- 2016-05-10 IL IL245587A patent/IL245587A0/en unknown
- 2016-05-10 US US15/150,497 patent/US20160250213A1/en not_active Abandoned
-
2018
- 2018-07-16 US US16/036,044 patent/US20180318301A1/en not_active Abandoned
-
2020
- 2020-09-30 US US17/038,749 patent/US20210008072A1/en not_active Abandoned
- 2020-10-21 IL IL278214A patent/IL278214A/en unknown
-
2021
- 2021-09-17 JP JP2021152005A patent/JP2021191796A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016537347A5 (enExample) | ||
| RU2016122609A (ru) | Составы соединений азаиндола | |
| TWI583384B (zh) | 包含４－胺基－５－氟－３－［６－（４－甲基哌嗪－１－基）－１ｈ－苯并咪唑－２－基］－１ｈ－喹啉－２－酮乳酸鹽單水合物之醫藥組合物 | |
| JP2014533733A5 (enExample) | ||
| JP2010031019A (ja) | 薬物高含量錠剤 | |
| JP2013526482A5 (enExample) | ||
| JP2018162255A5 (enExample) | ||
| JP2023116489A5 (enExample) | ||
| JP2016513734A5 (enExample) | ||
| JP2017537899A5 (enExample) | ||
| JP2015510916A5 (enExample) | ||
| JP2007091758A5 (enExample) | ||
| JP2020097577A5 (enExample) | ||
| US20160303077A1 (en) | Novel compositions | |
| JP2019526591A5 (enExample) | ||
| US20210308104A1 (en) | Pharmaceutical composition comprising eltrombopag olamine | |
| JP2021512869A5 (enExample) | ||
| JP2016050206A (ja) | レボカルニチンを含有する医薬錠剤 | |
| JP2017520619A5 (enExample) | ||
| AU2016231883A1 (en) | Pharmaceutical compositions of dimethyl fumarate | |
| JP2018012697A (ja) | 口腔内崩壊時間が短縮された、塩を含有する錠剤 | |
| JP5910311B2 (ja) | 医薬錠剤およびその製造方法 | |
| EP4054566A1 (en) | A capsule comprising eltrombopag olamine | |
| RU2731536C1 (ru) | Фармацевтические композиции, содержащие фенозановую кислоту | |
| JP7355846B2 (ja) | 固形製剤 |